glp-1 drugs made from Compounded" | Health Communication Research Laboratory The Power of Discovery: GLP-1

#CardiovascularDrugs #Cardiology #HeartHealth #PharmaceuticalIndustry #CardiovascularDisease #PharmaInnovation To view or add a comment, sign in : : The biosimilars market is expected to reach USD 72.29 billion by 2035 from USD 35.04 billion in 2025, at a CAGR of 7.5% during the forecast period

In higher risk patients, holding GLP-1 medications should balance risk vs benefit of surgical and medical risks and metabolic disease states

Large cardiovascular outcome trials, including LEADER (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide), have provided valuable insights into lipid changes

However, human experiments have not proven more than a modest effect on energy expenditure, not achieving clinical significance [28]

Peripheral effects alone may not be enough

In the PIONEER 1 trial, oral semaglutide 14mg as monotherapy reduced A1C by approximately 1.5% at 26 weeks, with progressive improvement reaching up to 1.8% in some analyses